Versartis, Inc. (NASDAQ:VSAR)’s share price traded up 0% on Thursday . The company traded as high as $1.85 and last traded at $1.85. 1,254,654 shares changed hands during trading, a decline of 8% from the average session volume of 1,360,597 shares. The stock had previously closed at $1.85.

A number of equities analysts recently weighed in on the stock. BidaskClub downgraded shares of Versartis from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Piper Jaffray Companies restated a “buy” rating and set a $26.00 target price on shares of Versartis in a report on Friday, September 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $14.00 price objective (down from $34.00) on shares of Versartis in a research report on Friday, September 22nd. Morgan Stanley reaffirmed an “equal weight” rating and set a $4.00 price objective (up from $3.00) on shares of Versartis in a research report on Friday, September 22nd. Finally, Zacks Investment Research cut shares of Versartis from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $7.22.

The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.39 and a current ratio of 2.39.

Versartis (NASDAQ:VSAR) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.78). During the same quarter last year, the company posted ($0.92) earnings per share. sell-side analysts expect that Versartis, Inc. will post -4.14 EPS for the current year.

In other Versartis news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total transaction of $7,007,700.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 2,132,769 shares of company stock worth $7,014,761 over the last 90 days. Company insiders own 10.90% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of VSAR. Vanguard Group Inc. raised its position in Versartis by 11.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock valued at $19,569,000 after buying an additional 118,894 shares during the last quarter. State Street Corp raised its position in Versartis by 6.9% in the 2nd quarter. State Street Corp now owns 556,718 shares of the biopharmaceutical company’s stock valued at $9,716,000 after buying an additional 35,957 shares during the last quarter. Northern Trust Corp raised its position in Versartis by 15.6% in the 2nd quarter. Northern Trust Corp now owns 420,553 shares of the biopharmaceutical company’s stock valued at $7,339,000 after buying an additional 56,761 shares during the last quarter. Artal Group S.A. raised its position in Versartis by 14.3% in the 3rd quarter. Artal Group S.A. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 50,000 shares during the last quarter. Finally, Sphera Funds Management LTD. raised its position in Versartis by 25.8% in the 2nd quarter. Sphera Funds Management LTD. now owns 377,524 shares of the biopharmaceutical company’s stock valued at $6,588,000 after buying an additional 77,524 shares during the last quarter. Institutional investors own 73.99% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Versartis, Inc. (VSAR) Trading 0% Higher” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/10/versartis-inc-vsar-trading-0-higher.html.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Receive News & Stock Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related stocks with our FREE daily email newsletter.